GCG and pseudotumor cerebri: Repurposing glucagon‐like peptide‐1 (GLP‐1) and GIP/GLP‐1 receptor agonists (RAs) for idiopathic intracranial hypertension (IIH) represents an attractive alternative to current treatments, supported by evidence of potent metabolic effects and reductions in cerebrospinal fluid secretion and intracranial pressure in vivo.